Arango-Argoty G, Kipkogei E, Stewart R, Sun G, Patra A, Kagiampakis I
Nat Commun. 2025; 16(1):2101.
PMID: 40025003
PMC: 11873189.
DOI: 10.1038/s41467-025-57181-2.
Kim Y, Song J, Kim N, Sim T
RSC Med Chem. 2025; .
PMID: 39925737
PMC: 11800140.
DOI: 10.1039/d4md00881b.
Gandara D, Agarwal N, Gupta S, Klempner S, Andrews M, Mahipal A
J Immunother Cancer. 2025; 13(2).
PMID: 39915003
PMC: 11815411.
DOI: 10.1136/jitc-2024-010311.
Lai X, Wang S, Zhang X, Zhu X, Liu Y, Chang Z
Front Immunol. 2025; 15:1514295.
PMID: 39902037
PMC: 11788372.
DOI: 10.3389/fimmu.2024.1514295.
Yoo S, Fitzgerald C, Cho B, Fitzgerald B, Han C, Koh E
Nat Med. 2025; .
PMID: 39762425
DOI: 10.1038/s41591-024-03398-5.
Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer.
Qu F, Wu S, Yu W
Onco Targets Ther. 2024; 17:1223-1253.
PMID: 39735789
PMC: 11681808.
DOI: 10.2147/OTT.S500281.
CD57 EMRA CD8 T cells in cancer patients over 70: associations with prior chemotherapy and response to anti-PD-1/PD-L1 therapy.
Gonnin C, Leemans M, Canoui-Poitrine F, Lebraud M, Corneau A, Roquebert L
Immun Ageing. 2024; 21(1):89.
PMID: 39731117
PMC: 11673364.
DOI: 10.1186/s12979-024-00487-4.
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer.
Rakaee M, Tafavvoghi M, Ricciuti B, Alessi J, Cortellini A, Citarella F
JAMA Oncol. 2024; 11(2):109-118.
PMID: 39724105
PMC: 11843371.
DOI: 10.1001/jamaoncol.2024.5356.
Combined systemic immune-inflammatory index and prognostic nutritional index predicts the efficacy and prognosis of ES-SCLC patients receiving PD-L1 inhibitors combined with first-line chemotherapy.
Ge Y, Liu X, Xu Y, Su Y, Li Y, Wang L
Front Oncol. 2024; 14:1485849.
PMID: 39697233
PMC: 11652344.
DOI: 10.3389/fonc.2024.1485849.
Tumor microenvironment assessment-based signatures for predicting response to immunotherapy in non-small cell lung cancer.
Wu J, Wang Y, Huang Z, Wu J, Sun H, Zhou R
iScience. 2024; 27(12):111340.
PMID: 39687018
PMC: 11647137.
DOI: 10.1016/j.isci.2024.111340.
THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data.
Wang Y, Guan Y, Lai X, Liu Y, Chang Z, Wang X
Brief Bioinform. 2024; 26(1).
PMID: 39679440
PMC: 11647273.
DOI: 10.1093/bib/bbae648.
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.
Barnett R, Jang A, Lanka S, Fu P, Bucheit L, Babiker H
Commun Med (Lond). 2024; 4(1):256.
PMID: 39623081
PMC: 11612475.
DOI: 10.1038/s43856-024-00687-5.
Mapping in silico genetic networks of the KMT2D tumour suppressor gene to uncover novel functional associations and cancer cell vulnerabilities.
Takemon Y, Pleasance E, Gagliardi A, Hughes C, Csizmok V, Wee K
Genome Med. 2024; 16(1):136.
PMID: 39578878
PMC: 11583415.
DOI: 10.1186/s13073-024-01401-9.
Prognostic biomarkers for immunotherapy in esophageal cancer.
Tong X, Jin M, Wang L, Zhang D, Yin Y, Shen Q
Front Immunol. 2024; 15:1420399.
PMID: 39403382
PMC: 11471503.
DOI: 10.3389/fimmu.2024.1420399.
Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer.
Wang Y, Song W, Feng C, Wu S, Qin Z, Liu T
J Transl Med. 2024; 22(1):900.
PMID: 39367493
PMC: 11452965.
DOI: 10.1186/s12967-024-05685-8.
Tumour mutational burden: clinical utility, challenges and emerging improvements.
Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altburger C
Nat Rev Clin Oncol. 2024; 21(10):725-742.
PMID: 39192001
DOI: 10.1038/s41571-024-00932-9.
Plasma extracellular vesicle long RNA profiling identifies a predictive signature for immunochemotherapy efficacy in lung squamous cell carcinoma.
Zhang X, Liao J, Yang W, Li Q, Wang Z, Yu H
Front Immunol. 2024; 15:1421604.
PMID: 39161762
PMC: 11331801.
DOI: 10.3389/fimmu.2024.1421604.
Differential impact of intratumor heterogeneity (ITH) on survival outcomes in early-stage lung squamous and adenocarcinoma based on tumor mutational burden (TMB).
Fridland S, Kim H, Chae Y
Transl Lung Cancer Res. 2024; 13(7):1481-1494.
PMID: 39118891
PMC: 11304137.
DOI: 10.21037/tlcr-24-226.
Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges.
Pathania A
Cancers (Basel). 2024; 16(12).
PMID: 38927907
PMC: 11201451.
DOI: 10.3390/cancers16122201.
The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer types.
Miyashita H, Bevins N, Thangathurai K, Lee S, Pabla S, Nesline M
Am J Cancer Res. 2024; 14(5):2240-2252.
PMID: 38859855
PMC: 11162686.
DOI: 10.62347/JRJP7877.
